About Event

Bolstering your Alzheimer’s & Parkinson’s Pipeline to Slow, Cure & Prevent Neurodegeneration

2023 has welcomed revolutionary advances in Alzheimer's & Parkinson’s drug development, from Lecanemab's 30% reduction in cognitive decline to the hotly awaited FDA decision on Eli Lilly’s Donanemab. As we move into 2024, it’s time to refocus with new energy to tackle the biggest industry bottlenecks limiting pipeline progress: brain delivery, ARIA, prognostic biomarker discovery, disease staging, neuroprotection, and resilience genes.

With 52+ KOLs speaking on the program from the likes of Biogen, Eisai, Eli Lilly, Acumen, and Alector, the 12th Alzheimer’s & Parkinson’s Drug Development forum is the ultimate biopharma-led meeting dedicated to overcoming industry-specific challenges.

This April, explore hiPSCs, 3D brain organoids, and translational blood-based biomarkers to diagnose, stage, and predict disease, accelerate novel targets and next-generation modalities into the clinic, and navigate new payer and approval discussions in AD & PD.

Discovery & Clinical Neuroscientists United To:

Integrate blood-based biomarkers into your R&D pipeline for the more quantitative and patient-specific staging of disease and drug effect, utilizing AI, ML, GWAS, and consortia findings for improved ID & validation with Eisai, Abbvie, Pfizer, Merck, Altpep, WashU, SunPharma, Herantis Pharma, and Michael J. Fox Foundation

Delve into innovations in CNS tech with deep-dive workshops on new techniques for blood-brain barrier delivery, gene therapies for neurodegeneration, and digital biomarkers for internal decision-making with Eli Lilly, Abbvie, Seelos Therapeutics, Imnewrun, CLAIRIgene, Attralus

Discover novel targets beyond pathological protein aggregates, from astrocytes, neuroinflammation, and microglia, to targeting protective variants resistant to neurodegeneration using ASOs, gene therapies, RNA-based treatment, and more with Vigil Neuro, Regeneron, Eisai, Merck, Alchemab, Eli Lilly, Novartis, Tranquis Therapeutics.

Refine translational modeling techniques with hiPSC-derived neurons, biprinted 3D brain models, brain-on-a-chip technology, and more translational in vivo models recapitulating heterogeneous disease pathology: tau propagation, ARIA, PFF modeling, and neuroimaging with Sanofi, MSD, Abbvie, Janssen, Biogen, UCB, Immunobrain, VaccineX

Hear the latest unpublished clinical research on next-generation anti-amyloid oligomer agents from Acumen, Alzheon, and ProMIS Neurosciences, new learnings on subcutaneous lecanemab with Eisai, the latest clinical data from compounds targeting microglia and targeted protein degradation with Alector and Aprinoia, and discussions of market access and US coverage dynamics with Eli Lilly

Who Will You Meet?
Graph 1
Graph 2
What Your Peers Have to Say: